Dr. Andreas Schmid, MD
Pulmonology (Pulmonary Disease Physician)
- Medicare participating
At a glance
- Years since graduation
- 28
- In the NPI registry since
- 2008
- Medicare patients seen, 2024
- 477
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pulmonary Disease Physician primary
KS license 04-41131 · FL license ME101785 -
Critical Care Medicine (Internal Medicine) Physician
FL license ME101785 -
Internal Medicine Physician
FL license ME101785
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University of Kansas Hospital Kansas City, KS
- University of Kansas Health System Olathe Hospital Olathe, KS
- Lmh Lawrence, KS
Medical groups
- Kansas University Physicians Inc (1,849 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 477
- Services billed
- 1,092
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 138 | 105 |
| Established patient office or other outpatient visit, 40-54 minutes | 117 | 72 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 113 | 55 |
| Critical care, first 30-74 minutes | 88 | 36 |
| Test to measure expiratory airflow and volume | 80 | 78 |
| Test to examine how well the lungs exchange gases | 75 | 75 |
| Test to determine lung volumes using sensors | 61 | 61 |
| Critical care, each additional 30 minutes | 54 | 13 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 30 | 30 |
| New patient office or other outpatient visit, 60-74 minutes | 26 | 26 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Azithromycin Other prescribers in Kansas City, KS | 193 |
| Ethambutol Hcl | 83 |
| Albuterol Sulfate Hfa (albuterol sulfate) Other prescribers in Kansas City, KS | 65 |
| Spiriva Respimat (tiotropium bromide) Other prescribers in Kansas City, KS | 56 |
| Stiolto Respimat (tiotropium br/olodaterol hcl) Other prescribers in Kansas City, KS | 53 |
| Symbicort (budesonide/formoterol fumarate) Other prescribers in Kansas City, KS | 48 |
| Anoro Ellipta (umeclidinium brm/vilanterol tr) Other prescribers in Kansas City, KS | 40 |
| Prednisone Other prescribers in Kansas City, KS | 37 |
| Trikafta (elexacaftor/tezacaftor/ivacaft) | 34 |
| Doxycycline Hyclate Other prescribers in Kansas City, KS | 25 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 4 payments worth $72.62 in total to this clinician.
| Insmed, Inc. | $72.62 |
|---|
| Food and Beverage | $72.62 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 10 industry-funded studies in 2025, from 9 companies. The companies reported $330,469 in research payments for these studies, mostly to the institutions running them.
- Verona
Verona Pharma, Inc. - Study to Evaluate ALIS (Amikacin Liposome Inhalation Suspension) in Participants With Nontuberculous Mycobacterial Lung Infection Caused by Mycobacterium Avium Complex
Insmed, Inc. · Completed · NCT04677569 - ICoN-1 Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation Suspension
Mannkind Corporation · Terminated · NCT06418711 - A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Non-cystic Fibrosis Bronchiectasis
Sanofi US Services Inc. · Completed · NCT06280391 - A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM)
Boehringer Ingelheim Pharmaceuticals, Inc. - Dose Range Finding, Efficacy, and Safety Study of Nebulized CSL787 in Adults With Non-cystic Fibrosis Bronchiectasis (NCFB)
Csl Behring · Recruiting · NCT07048262 - Ph1c proof of activity study of GDC-6988 in patients with COPD and NCFB
Genentech, Inc. - A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIR…
Boehringer Ingelheim International GmbH - A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM)
Boehringer Ingelheim International GmbH - A Randomized, Double-Blind, Two-way Crossover Study to Assess the Effect of Hydrofluoroolefin (HFO) Propellant Metered Dose Inhaler (MDI) on Mucociliary Clearance Compared with Hydrofluoroalkane (HFA) Propellant MDI i…
AstraZeneca UK Limited
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.